This page was translated automatically from Turkish. Read the original

This page is an AI-assisted Turkish summary of the study presented at the 26th World Congress of Psychiatry. The study belongs to the presenting authors; please refer to the original source when citing it.

EV0399

Vortioxetine for post-COVID cognitive dysfunction and depressive symptoms: a case report

VORTIOXETINE IN POST COVID COGNITIVE DYSFUNCTION AND DEPRESSIVE SYMPTOMS A CASE REPORT

In a patient with post-COVID cognitive complaints and depressive symptoms, vortioxetine treatment was associated with improvements in depressive symptoms and cognitive performance over a 10-week follow-up and was well tolerated.

The poster describes clinical improvement with vortioxetine treatment in a patient with persistent cognitive symptoms (brain fog) and depressive features following COVID-19. The longitudinal clinical course of a 46-year-old man who developed impaired attention, slowed thinking, mental fatigue, reduced work performance, and depressive symptoms following COVID-19 was monitored. Assessment included a psychiatric interview, repeated clinical assessments, monitoring of functioning, and the Digit Symbol Substitution Test (DSST). Vortioxetine was initiated and titrated to 20 mg/day according to tolerability and clinical response. During follow-up, depressive symptoms improved alongside subjective cognitive complaints, and the DSST score increased from 44 at baseline to 51 after 10 weeks of treatment, indicating improvement in attention and processing speed. The patient reported better concentration, less mental fatigue, and increased work productivity and daily functioning, with no clinically significant adverse effects observed. The author notes that vortioxetine may be of interest, particularly when fatigue and functional impairment are prominent, and that its role needs to be clarified through prospective studies.

All WCP 2026 summaries